Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases.

Authors

Andrea Vecchione, Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA, 19107, USA, University of Rome "La Sapienza", Ospedale Santo Andrea, Rome, ItalyFollow
Tommaso Prayer Galetti, Department of Urology, University of Padova, Via Giustiniani 25, Padova, ItalyFollow
Marina Gardiman, Department of Pathology, University of Padova, Via Gabelli 3, Padova, ItalyFollow
Hideshi Ishii, Department of Microbiology/Immunology, Kimmel Cancer Center, Thomas Jefferson University, 220 10th South Street, Philadelphia, PA, 19107, USA, Jichi Medical School, Center for Molecular Medicine, Division of Stem Cell Regulation/Molecular Hematopoiesis, 3311-1 Yakushiji, Minami-Kawachi, Tochigi, 329-0498, JapanFollow
Enrico Giarnieri, Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA, 19107, USA, University of Rome "La Sapienza", Ospedale Santo Andrea, Rome, ItalyFollow
Francesco Pagano, Department of Urology, University of Padova, Via Giustiniani 25, Padova, ItalyFollow
Leonard G Gomella, Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA, 19107, USAFollow
Carlo M Croce, Department of Microbiology/Immunology, Kimmel Cancer Center, Thomas Jefferson University, 220 10th South Street, Philadelphia, PA, 19107, USAFollow
Raffaele BaffaFollow

Document Type

Article

Publication Date

9-9-2004

Comments

This article has been peer reviewed and is published in BMC Urology. Volume 4, 9 September 2004, Article number 11. The published version is available at DOI: 10.1186/1471-2490-4-11. Copyright © BioMed Central Ltd.

Abstract

BACKGROUND: Collecting duct carcinoma (CDC) is a rare but very aggressive variant of kidney carcinoma that arises from the epithelium of Bellini's ducts, in the distal portion of the nephron. In order to gain an insight into the biology of this tumor we evaluated the expression of five genes involved in the development of renal cancer (FEZ1/LZTS1, FHIT, TP53, P27kip1, and BCL2). METHODS: We studied eleven patients who underwent radical nephrectomy for primary CDC. All patients had an adequate clinical follow-up and none of them received any systemic therapy before surgery. The expression of the five markers for tumor initiation and/or progression were assessed by immunohistochemistry and correlated to the clinicopathological parameters, and survival by univariate analysis. RESULTS: Results showed that Fez1 protein expression was undetectable or substantially reduced in 7 of the 11 (64%) cases. Fhit protein was absent in three cases (27%). The overexpression of p53 protein was predominantly nuclear and detected in 4 of 11 cases (36%). Immunostaining for p27 was absent in 5 of 11 cases (45.5%). Five of the six remaining cases (90%) showed exclusively cytoplasmic protein expression, where, in the last case, p27 protein was detected in both nucleus and cytoplasm. Bcl2 expression with 100% of the tumor cells positive was observed in 4 of 11 (36%) cases. Statistical analysis showed a statistical trend (P = 0.06) between loss and reduction of Fez1 and presence of lymph node metastases. CONCLUSIONS: These findings suggest that Fez1 may represent not only a molecular diagnostic marker but also a prognostic marker in CDC.

Recommended Citation

Vecchione, Andrea; Galetti, Tommaso Prayer; Gardiman, Marina; Ishii, Hideshi; Giarnieri, Enrico; Pagano, Francesco; Gomella, Leonard G; Croce, Carlo M; and Baffa, Raffaele, "Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases." (2004). Department of Urology Faculty Papers. Paper 6.
https://jdc.jefferson.edu/urologyfp/6

PubMed ID

15357873